Premium
Biodistribution of monoclonal antibody A7 and its F(ab′) 2 fragment in athymic nude mice bearing human pancreatic carcinoma
Author(s) -
Otsuji Eigo,
Yamaguchi Toshiharu,
Yamaoka Nobuki,
Yamaguchi Nozomi,
Imanishi Jiro,
Takahashi Toshio
Publication year - 1992
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930500309
Subject(s) - monoclonal antibody , biodistribution , medicine , pathology , in vivo , antibody , carcinoma , monoclonal , intraperitoneal injection , pancreas , pancreatic disease , pancreatic tumor , microbiology and biotechnology , chemotherapy , cancer research , pancreatic cancer , immunology , biology , cancer
Xenografts of a human pancreatic carcinoma cell line, HPC‐YS, which reacted with the monoclonal antibody (MAb) A7, were used to investigate the in vivo localization of radioiodinated MAb A7 after intraperitoneal injection. MAb A7 localized to the tumor 4 days and 8 days after injection with a tissue/blood ratio of 1.45 ± 0.18 and 2.04 ± 0.20, respectively. The accumulation of MAb A7 in the tumor was 5%/g and 3.3%/g of the injected dose on day 4 and on day 8, respectively. In contrast, the F(ab') 2 fragment of MAb A7 localized to the tumor 4 days after intravenous injection with a tissue/blood ratio of 14.2. The accumulation of the F(ab') 2 fragment in the tumor was 1.2%/g of the injected dose. These results suggested that MAb A7 might be a suitable carrier of anticancer drugs for immunotargeting chemotherapy and that the F(ab') 2 fragment might be potentially useful for the immunodetection of human pancreatic carcinomas. © 1992 Wiley‐Liss, Inc.